http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-27T19:47:43.590Z

http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

ranitidine tablets are indicated in 1 short term treatment of active duodenal ulcer most patients heal within 4 weeks studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks 2 maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers no placebo controlled comparative studies have been carried out for periods of longer than 1 year 3 the treatment of pathological hypersecretory conditions e g zollinger ellison syndrome and systemic mastocytosis 4 short term treatment of active benign gastric ulcer most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks 5 maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers placebo controlled studies have been carried out for 1 year 6 treatment of gerd symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine tablets 15 mg twice daily 7 treatment of endoscopically diagnosed erosive esophagitis symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine tablets 15 mg 4 times daily 8 maintenance of healing of erosive esophagitis placebo controlled trials have been carried out for 48 weeks concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer active benign gastric ulcer hypersecretory states gerd and erosive esophagitis

Leoni Bücken

2021-06-27T19:47:43.590Z

http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_8534 DOID_8534

Leoni Bücken

2021-06-27T19:47:43.590Z

http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-27T19:47:43.590Z

http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00863 drugbank:DB00863

Leoni Bücken

2021-06-27T19:47:43.590Z

http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-27T19:47:43.590Z

http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-27T19:47:43.590Z

http://purl.org/np/RAjoMC9IDz... RAjoMC9IDz

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication

Leoni Bücken

2021-06-27T19:47:43.590Z